Important Copyright Message

FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS

The Medical Letter, Inc. publications are protected by U.S. and international copyright laws. Forwarding, copying or any distribution of this material is prohibited.

Sharing a password with a non-subscriber or otherwise making the contents of this site available to third parties is strictly prohibited.

By accessing and reading the attached content I agree to comply with U.S. and international copyright laws and these terms and conditions of The Medical Letter, Inc.

For further information click: Subscriptions, Site Licenses, Reprints or call customer service at: 800-211-2769
IN BRIEF

Repatha Pushtronex – A New Evolocumab Injection Device

The PCSK9 inhibitor evolocumab (Repatha – Amgen) is now available in a single-dose, hands-free device (Repatha Pushtronex) for once-monthly subcutaneous infusion. Evolocumab is FDA-approved as an adjunct to diet and maximally tolerated statin therapy for patients with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease who require additional lowering of low-density lipoprotein cholesterol (LDL-C), and as an adjunct to diet and other LDL-lowering therapies for patients with homozygous familial hypercholesterolemia (HoFH).

Evolocumab is also available in 140-mg single-use prefilled syringes and autoinjectors (Repatha Sureclick).\(^1\) Use of these formulations to administer the once-monthly dose (420 mg) requires patients to inject themselves three consecutive times within 30 minutes. Another PCSK9 inhibitor, alirocumab (Praluent), is injected every 2 weeks; it is available in single-dose prefilled syringes and pens.

Table 1. Evolocumab Products

<table>
<thead>
<tr>
<th>Drug</th>
<th>Formulations</th>
<th>Usual Adult Dosage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Repatha (Amgen)</td>
<td>140 mg/mL single-use prefilled syringe</td>
<td>140 mg SC q2 wks or 420 mg SC once/month(^1,2)</td>
</tr>
<tr>
<td>Repatha Sureclick</td>
<td>140 mg/mL single-use prefilled autoinjector</td>
<td>140 mg SC q2 wks or 420 mg SC once/month(^1,2)</td>
</tr>
<tr>
<td>Repatha Pushtronex</td>
<td>420 mg/3.5 mL single-use infusor with prefilled cartridge</td>
<td>420 mg SC once/month</td>
</tr>
</tbody>
</table>

1. Dosage for patients with HeFH or atherosclerotic cardiovascular disease.
2. The 420-mg dose is given as three consecutive 140-mg injections within 30 minutes.

The Repatha Pushtronex system consists of a single-use, battery-powered infusor and a prefilled cartridge containing a 420-mg dose of evolocumab. Once assembled, the patient adheres the device to the skin of the abdomen, thigh, or upper arm and presses a button to begin the subcutaneous injection; infusion of the dose takes about 9 minutes. One Repatha Pushtronex device costs $1175. Three 140-mg Repatha Sureclick autoinjectors or Repatha prefilled syringes cost $1627.\(^2\)